Trius Therapeutics to Present at October 2011 Investor Conferences
17 oct. 2011 16h07 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Oct. 17, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company will present at the following investor conferences:
Newsmakers in the...
Trius Initiates Second Phase 3 Trial in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
29 sept. 2011 16h01 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Sept. 29, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the dosing of the first patient in a second global Phase 3 pivotal trial in acute bacterial skin...
Trius to Present at the JMP Securities Healthcare Conference
23 sept. 2011 16h01 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Sept. 23, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will...
Trius Announces Completion of Enrollment in Phase 3 Trial
15 sept. 2011 16h02 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Sept. 15, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company has completed the enrollment of the first of two planned Phase 3 trials of...
Trius Therapeutics to Present Data From Antibiotic Drug Development Programs at ICAAC
14 sept. 2011 09h01 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its drug development programs, including its lead...
Trius Therapeutics Reports 2011 Second Quarter Financial Results
11 août 2011 16h01 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius to Present at Canaccord Genuity Growth Conference
05 août 2011 16h05 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Therapeutics Obtains Special Protocol Assessment With FDA for Second Phase 3 Study of Torezolid Phosphate
05 août 2011 06h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 5, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the...
Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia-Pacific and Emerging Markets
27 juil. 2011 06h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, July 27, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) and Bayer Pharma AG today announced that they have signed an exclusive agreement to develop and commercialize Trius'...
New Research Indicates Potential for Continued Spread of Multidrug Resistant Strain of Staph Aureus
19 juil. 2011 16h21 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, July 19, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...